Enfortumab-vedotin plus pembrolizumab offers survival benefits but is less cost-effective than gemcitabine and cisplatin plus nivolumab, especially in Europe. Healthcare providers face challenges ...
Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib. In patients with relapsed/refractory Waldenström macroglobulinemia ...
Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...
A joint model combining decision tree with partitioned survival models was developed. A two-round consensus panel was performed to describe clinical practice of Spanish reference centers, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback